Logo image of BMEA

BIOMEA FUSION INC (BMEA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BMEA - US09077A1060 - Common Stock

1.07 USD
+0.04 (+3.88%)
Last: 11/26/2025, 8:17:47 PM
1.1 USD
+0.03 (+2.8%)
After Hours: 11/26/2025, 8:17:47 PM
Fundamental Rating

2

Overall BMEA gets a fundamental rating of 2 out of 10. We evaluated BMEA against 533 industry peers in the Biotechnology industry. While BMEA seems to be doing ok healthwise, there are quite some concerns on its profitability. BMEA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BMEA had negative earnings in the past year.
BMEA had a negative operating cash flow in the past year.
BMEA had negative earnings in each of the past 5 years.
BMEA had a negative operating cash flow in each of the past 5 years.
BMEA Yearly Net Income VS EBIT VS OCF VS FCFBMEA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of BMEA (-173.43%) is worse than 87.24% of its industry peers.
With a Return On Equity value of -612.79%, BMEA is not doing good in the industry: 78.42% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -173.43%
ROE -612.79%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-65.2%
ROE(3y)-137.7%
ROE(5y)-89.02%
ROIC(3y)N/A
ROIC(5y)N/A
BMEA Yearly ROA, ROE, ROICBMEA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 0 0 0 0

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BMEA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMEA Yearly Profit, Operating, Gross MarginsBMEA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for BMEA has been increased compared to 1 year ago.
The number of shares outstanding for BMEA has been increased compared to 5 years ago.
There is no outstanding debt for BMEA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BMEA Yearly Shares OutstandingBMEA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
BMEA Yearly Total Debt VS Total AssetsBMEA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

BMEA has an Altman-Z score of -15.61. This is a bad value and indicates that BMEA is not financially healthy and even has some risk of bankruptcy.
BMEA has a worse Altman-Z score (-15.61) than 80.49% of its industry peers.
BMEA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.61
ROIC/WACCN/A
WACCN/A
BMEA Yearly LT Debt VS Equity VS FCFBMEA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

BMEA has a Current Ratio of 3.18. This indicates that BMEA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BMEA (3.18) is worse than 61.73% of its industry peers.
A Quick Ratio of 3.18 indicates that BMEA has no problem at all paying its short term obligations.
BMEA's Quick ratio of 3.18 is in line compared to the rest of the industry. BMEA outperforms 41.28% of its industry peers.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 3.18
BMEA Yearly Current Assets VS Current LiabilitesBMEA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.40% over the past year.
EPS 1Y (TTM)40.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BMEA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.35% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.75%
EPS Next 2Y28.1%
EPS Next 3Y17.03%
EPS Next 5Y11.35%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMEA Yearly Revenue VS EstimatesBMEA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 200M 400M 600M
BMEA Yearly EPS VS EstimatesBMEA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BMEA. In the last year negative earnings were reported.
Also next year BMEA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMEA Price Earnings VS Forward Price EarningsBMEA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMEA Per share dataBMEA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

BMEA's earnings are expected to grow with 17.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.1%
EPS Next 3Y17.03%

More info and screens

0

5. Dividend

5.1 Amount

BMEA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMEA FUSION INC

NASDAQ:BMEA (11/26/2025, 8:17:47 PM)

After market: 1.1 +0.03 (+2.8%)

1.07

+0.04 (+3.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-31 2026-03-31/amc
Inst Owners48.33%
Inst Owner Change-12.48%
Ins Owners4.47%
Ins Owner Change0%
Market Cap74.17M
Revenue(TTM)N/A
Net Income(TTM)-95.71M
Analysts84.62
Price Target7.14 (567.29%)
Short Float %13.27%
Short Ratio4.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.15%
Min EPS beat(2)-3.47%
Max EPS beat(2)5.77%
EPS beat(4)2
Avg EPS beat(4)-3.03%
Min EPS beat(4)-28.2%
Max EPS beat(4)13.79%
EPS beat(8)4
Avg EPS beat(8)-2.58%
EPS beat(12)6
Avg EPS beat(12)-1.37%
EPS beat(16)7
Avg EPS beat(16)-2.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.5%
PT rev (3m)-8.7%
EPS NQ rev (1m)-1.75%
EPS NQ rev (3m)4.76%
EPS NY rev (1m)0%
EPS NY rev (3m)3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.75
P/tB 4.75
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS0
BVpS0.23
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -173.43%
ROE -612.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-65.2%
ROE(3y)-137.7%
ROE(5y)-89.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 3.18
Altman-Z -15.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)130.81%
Cap/Depr(5y)432.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.33%
EPS Next Y58.75%
EPS Next 2Y28.1%
EPS Next 3Y17.03%
EPS Next 5Y11.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.48%
EBIT Next 3Y8.41%
EBIT Next 5Y3.67%
FCF growth 1Y11.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.01%
OCF growth 3YN/A
OCF growth 5YN/A

BIOMEA FUSION INC / BMEA FAQ

What is the fundamental rating for BMEA stock?

ChartMill assigns a fundamental rating of 2 / 10 to BMEA.


What is the valuation status for BMEA stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOMEA FUSION INC (BMEA). This can be considered as Overvalued.


How profitable is BIOMEA FUSION INC (BMEA) stock?

BIOMEA FUSION INC (BMEA) has a profitability rating of 0 / 10.


What is the expected EPS growth for BIOMEA FUSION INC (BMEA) stock?

The Earnings per Share (EPS) of BIOMEA FUSION INC (BMEA) is expected to grow by 58.75% in the next year.